查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926858

大肠直肠癌分子诊断市场按技术、产品类型、应用、生物标记、检体类型和最终用户划分－2026-2032年全球预测

Colorectal Cancer Molecular Diagnostics Market by Technology, Product Type, Application, Biomarker, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，大肠直肠癌分子诊断市场价值将达到 31.1 亿美元，到 2026 年将成长至 33.1 亿美元，到 2032 年将达到 49.4 亿美元，复合年增长率为 6.82%。

关键市场统计数据
基准年 2025 31.1亿美元
预计年份：2026年 33.1亿美元
预测年份 2032 49.4亿美元
复合年增长率 (%) 6.82%

本文简要概述了正在改变大肠直肠癌分子诊断和治疗路径的临床、技术和商业性因素。

分子诊断技术的进步正在重塑结直肠癌的临床实践，使检测、预后和治疗决策更加精准。过去十年，诊断模式已从基于形态学的评估转向基于分子的策略，包括标靶基因组分析、微卫星不稳定性分析和循环肿瘤DNA分析。这些技术提高了临床医生对患者进行分层、识别可治疗突变以及监测残留病灶的能力，其灵敏度远超传统方法。

技术进步、生物资讯整合以及不断变化的监管要求将如何融合，从而重新定义大肠直肠癌诊断的临床效用和商业策略？

大肠直肠癌分子诊断领域正经历一系列变革，这些变革的驱动力包括技术的成熟、临床证据的不断累积以及监管要求的不断演变。次世代定序平台已超越其最初的应用阶段，成为建构全面基因组分析方案的基础；数位PCR和定量PCR持续为标靶突变检测和微量残存疾病监测提供灵敏且经济高效的工具。同时，萤光原位杂合反应（FISH）和微阵列技术在特定的基因组背景下仍保持其独特的效用，从而构建了一个多层次的诊断生态系统，能够满足广泛和针对性强的临床需求。

2025年关税调整评估：诊断相关人员的供应链重组策略、区域製造决策与总拥有成本计算

2025年的关税政策变化为那些维护跨境仪器、耗材和定序试剂供应链的公司带来了特殊的复杂性。进口关税和贸易措施的变化会影响资本财的价格波动、关键试剂的到岸成本以及製造地的经济效益。对于依赖模组化全球供应链的製造商而言，即使是小幅的关税上涨也可能需要重新评估筹资策略、库存缓衝和合约条款，以保护利润并维持对临床检查室和医院系统的服务水准。

透过全面的細項分析，识别技术、产品、应用、生物标记、检体类型和最终用户之间的交集，从而指导策略性产品定位和临床应用。

对市场区隔的深入理解揭示了结直肠癌分子诊断领域中临床需求、技术能力和商业性机会的交汇点。从技术面来看，该领域涵盖萤光原位杂合反应(FISH)、微阵列、次世代定序(NGS) 和聚合酵素链锁反应(PCR) 技术。次世代定序技术本身已扩展到标靶定序、全EXOME定序和全基因测序，每种技术在深度、广度和成本方面各有优劣。聚合酵素链锁反应(PCR) 技术，包括数位 PCR 和定量 PCR，对于灵敏的靶向突变检测以及那些优先考虑快速结果和易于分析的应用仍然至关重要。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的诊断技术应用路径、监管应对措施和商业化选择。

区域趋势对分子诊断的普及率、监管路径和商业模式有着深远的影响。在美洲，成熟的临床网路和大规模参考实验室正在推动复杂基因组检测的早期应用，并将伴随诊断整合到癌症治疗路径中。该地区的新参与企业往往面临支付方结构分散和机构采购惯例各异的问题，即使临床指南越来越建议分子检测，也可能导致患者获得检测的机会不均等。

策略竞争考察：揭示平台整合商、试剂专家、生物资讯学供应商和检测实验室网路如何塑造市场定位和合作机会

大肠直肠癌分子诊断领域的竞争格局呈现出多元化的组织频谱，包括成熟的平台製造商、试剂专家、生物资讯公司、参考检查室网路以及灵活的Start-Ups公司。平台製造商正致力于开发整合解决方案，将定序仪和PCR系统与检验的耗材和判读软体结合，以降低临床检查室采用这些技术的门槛。试剂和试剂盒供应商则优先考虑分析性能、供应可靠性和简化的工作流程，这些工作对于寻求稳定日常检测量和符合法规要求的检查室至关重要。

透过提供产品整合、供应链韧性、证据产生和支付方参与等方面的切实可行的策略建议，加速临床应用和商业性成功。

产业领导者应检验将分析的稳健性与简化的临床工作流程结合的整合产品，并将验证后的仪器、耗材和软体整合为统一的解决方案。投资于能够降低检查室设置复杂性并提供清晰解读指南的承包检测包，将有助于降低医院和诊断中心采用这些产品的门槛。此外，企业还应努力产生将检测结果与可操作的治疗决策和可证实的患者疗效联繫起来的临床证据，从而增强报销理由并提升临床医生的信心。

采用严谨的混合调查方法，结合专家访谈、系统性文献回顾和交叉检验的品质检查，以确保临床和商业性相关性。

本分析的调查方法结合了定性专家访谈和对已发表的科学文献、监管文件以及不断更新的临床指南的系统性综合分析。关键输入包括对临床肿瘤学、分子病理学、生物资讯学和检查室运营等领域的关键行业专家进行结构化访谈，以确定实际应用中的驱动因素、营运限制和未满足的需求。这些专家见解与同侪审查的研究和监管通告进行交叉比对，以确保其与目前的临床实践和核准框架保持一致。

本文综合分析了关键见解，重点阐述了技术成熟度、证据产生、供应链韧性和区域策略的交汇点，这些因素共同决定了市场成功。

大肠直肠癌分子诊断正处于技术进步与临床应用价值验证的关键节点。次世代定序和先进的PCR技术等互补优势，支持从伴随诊断到微量残存疾病监测等广泛的临床应用。儘管日趋成熟的生物资讯学和解读服务显着提升了分子检测结果的临床效用，但区域监管差异和支付方差异仍影响其应用前景。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依技术分類的大肠直肠癌分子诊断市场

  • 萤光原位杂合反应
  • 微阵列
  • 次世代定序
    • 标靶定序
    • 全外EXOME定序
    • 全基因测序
  • 聚合酵素链锁反应
    • 数位PCR
    • 定量PCR

9. 依产品类型分類的大肠直肠癌分子诊断市场

  • 装置
    • PCR系统
    • 序列器
  • 试剂盒和试剂
  • 软体服务
    • 生物资讯服务
    • 数据分析软体

第十章 依应用分類的大肠直肠癌分子诊断市场

  • 伴随诊断
  • 预测性测试
  • 预后测试
  • 残留疾病监测

第十一章 大肠直肠癌分子诊断市场（依生物标记划分）

  • BRAF
  • KRAS
  • 微卫星不稳定性
  • NRAS

第十二章 依检体类型分類的大肠直肠癌分子诊断市场

  • 血
    • 电浆
    • 血清
  • 航班
  • 组织

第十三章 大肠直肠癌分子诊断市场（依最终用户划分）

  • 学术研究机构
  • 诊断中心
  • 医院和诊所
  • 参考检验机构

第十四章 大肠直肠癌分子诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 大肠直肠癌分子诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国大肠直肠癌分子诊断市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国大肠直肠癌分子诊断市场

第十八章：中国大肠直肠癌分子诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4F7A6D4FF33B

The Colorectal Cancer Molecular Diagnostics Market was valued at USD 3.11 billion in 2025 and is projected to grow to USD 3.31 billion in 2026, with a CAGR of 6.82%, reaching USD 4.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.11 billion
Estimated Year [2026] USD 3.31 billion
Forecast Year [2032] USD 4.94 billion
CAGR (%) 6.82%

A succinct orientation to the evolving clinical, technological, and commercial forces transforming colorectal cancer molecular diagnostics and care pathways

Advances in molecular diagnostics are reshaping clinical practice for colorectal cancer by enabling more precise detection, prognosis, and therapeutic decision-making. Over the last decade, diagnostic paradigms have shifted from morphology-driven assessments toward molecularly informed strategies that incorporate targeted genomic profiling, microsatellite instability evaluation, and circulating tumor DNA analysis. These capabilities are enhancing the clinician's ability to stratify patients, identify actionable alterations, and monitor residual disease with greater sensitivity than conventional approaches.

Transitioning from laboratory innovation to routine clinical use requires alignment across technology platforms, clinical validation pathways, regulatory frameworks, and payer engagement. As such, stakeholders spanning instrument manufacturers, kit and reagent suppliers, bioinformatics firms, clinical laboratories, and healthcare providers must coordinate efforts to ensure robustness, reproducibility, and clinical utility. The increasing convergence of sequencing platforms, digital PCR modalities, and integrated bioinformatics is lowering time-to-result and improving the granularity of molecular readouts, which in turn supports personalized treatment pathways and more efficient clinical workflows.

Given these dynamics, an executive-level synthesis of technological trajectories, adoption barriers, and use-case evidence is essential for strategic planning. This summary frames the prevailing scientific trends, commercial inflection points, and practical considerations that industry leaders and health-system decision-makers should weigh when prioritizing investments or forming collaborative alliances in the colorectal cancer molecular diagnostics arena.

How converging technology advances, integrated bioinformatics, and shifting regulatory expectations are redefining clinical utility and commercial strategies in colorectal cancer diagnostics

The landscape for colorectal cancer molecular diagnostics is experiencing a series of transformative shifts driven by technological maturation, expanding clinical evidence, and evolving regulatory expectations. Next-generation sequencing platforms have moved beyond early-adopter use to form the backbone of comprehensive genomic profiling programs, while digital PCR and quantitative PCR have continued to provide sensitive, cost-efficient tools for targeted mutation detection and minimal residual disease monitoring. Concurrently, fluorescence in situ hybridization and microarray technologies retain niche utility for specific genomic contexts, creating a layered diagnostic ecosystem that supports both broad and focused clinical questions.

Alongside platform evolution, bioinformatics and data analytics have emerged as critical differentiators. The ability to integrate variant calling, copy-number assessment, and clinically annotated interpretation at scale is accelerating clinical utility and enabling laboratories to deliver actionable reports in clinically relevant timeframes. In parallel, advances in liquid biopsy methodologies allow serial sampling via plasma and serum, making longitudinal monitoring of disease dynamics clinically feasible and less invasive. These shifts are prompting diagnostics providers to develop more integrated solutions that combine hardware, chemistry, and software in validated workflows.

Regulatory frameworks and payer expectations are adapting in response to growing clinical evidence, but heterogeneity in regional pathways and reimbursement policies continues to influence adoption rates. As stakeholders respond to these shifts, strategic imperatives include prioritizing high-value applications such as companion diagnostics for targeted therapies, robust analytical and clinical validation for residual disease assays, and investment in scalable laboratory operations and data infrastructure to support broader clinical deployment. The cumulative effect is a market environment that rewards interoperability, clinical outcome linkage, and proof of utility over isolated technical capability alone.

Assessment of 2025 tariff adjustments that are reshaping supply chain strategies, regional manufacturing decisions, and total-cost-of-ownership calculations for diagnostics stakeholders

Tariff policy shifts in 2025 have introduced tangible complexity for companies that maintain cross-border supply chains for instruments, consumables, and sequencing reagents. Changes in import duties and trade measures affect capital equipment pricing dynamics, the landed cost of critical reagents, and the economics of manufacturing footprints. For manufacturers that depend on modular global supply chains, even modest tariff increases can require re-evaluation of sourcing strategies, inventory buffers, and contract terms to protect margins and maintain service levels for clinical laboratories and hospital systems.

In response, many organizations are reassessing their operational models to increase regional resilience. Potential strategies include nearshoring production of high-volume consumables, expanding regional assembly hubs for instruments, and negotiating long-term supply agreements that hedge against tariff volatility. These adjustments aim to stabilize pricing for end users and reduce lead-time exposure, but they also require capital allocation and careful regulatory alignment to ensure that product specifications and quality management systems remain consistent across manufacturing sites.

Moreover, tariffs can indirectly influence innovation decisions by altering the economics of bringing new assays or platforms to market. Developers may prioritize software-driven differentiation and consumables with higher gross margins to offset increased import costs for hardware, or they may focus on strategic partnerships with local manufacturers to maintain competitive pricing. For clinical laboratories and institutional purchasers, procurement teams will likely place greater emphasis on total-cost-of-ownership analyses, including maintenance, consumables, and potential duty impacts, when evaluating instrument and assay purchases. In sum, tariff changes in 2025 have amplified the need for supply chain agility and strategic sourcing in the molecular diagnostics value chain.

Comprehensive segmentation analysis identifying technology, product, application, biomarker, sample type, and end-user intersections that inform strategic product positioning and clinical adoption

A nuanced understanding of market segmentation reveals where clinical demand, technological capability, and commercial opportunity intersect within colorectal cancer molecular diagnostics. Based on technologies, the field spans fluorescence in situ hybridization, microarray, next-generation sequencing, and polymerase chain reaction techniques. Next-generation sequencing itself is deployed across targeted sequencing, whole exome sequencing, and whole genome sequencing approaches, each offering distinct trade-offs between depth, breadth, and cost. Polymerase chain reaction modalities, including digital PCR and quantitative PCR, remain essential for highly sensitive, targeted mutation detection and for applications where rapid turnaround and lower analytical complexity are priorities.

When framed by product type, the ecosystem includes instruments, kits and reagents, and software services. Instruments commonly comprise PCR systems and sequencers that form the hardware backbone of both centralized and decentralized laboratories. Kits and reagents supply the chemistry necessary for reliable performance, while software services encompass bioinformatics services and data analysis software that translate raw signals into clinically meaningful insights. This integration of hardware, chemistry, and informatics is a recurring theme across commercial models and is pivotal in driving laboratory workflow efficiency and report interpretability.

Application-oriented segmentation highlights areas where clinical evidence is driving adoption. Companion diagnostics continue to be a high-priority application due to their direct linkage to targeted therapies, whereas predictive and prognostic testing expand personalized treatment selection and risk stratification. Residual disease monitoring is gaining traction as clinicians seek validated methods to detect minimal residual disease and to inform adjuvant therapy decisions. Biomarker segmentation emphasizes clinically actionable targets such as BRAF, KRAS, microsatellite instability, and NRAS, each representing specific diagnostic and therapeutic decision points in colorectal cancer management.

Sample type considerations influence upstream and downstream assay design. Diagnostic workflows accommodate blood-based testing, including plasma and serum, as well as stool and tissue samples. The rise of liquid biopsy approaches based on plasma has implications for assay sensitivity, pre-analytical handling, and longitudinal monitoring protocols. Finally, end-user segmentation delineates the operational contexts in which these technologies are deployed: academic research institutes drive innovation and validation studies; diagnostic centers and reference laboratories scale clinical testing; and hospitals and clinics integrate results into patient care pathways. Collectively, these segmentation lenses inform product development priorities, commercialization strategies, and partnership models for stakeholders seeking to align offerings with clinical demand.

Regional dynamics shaping diagnostic adoption pathways, regulatory navigation, and commercialization choices across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exert a profound influence on adoption velocities, regulatory pathways, and commercial models for molecular diagnostics. In the Americas, established clinical networks and large reference laboratories facilitate early adoption of complex genomic assays and the integration of companion diagnostics into oncology treatment pathways. Market participants in this region often contend with fragmented payer landscapes and institution-specific procurement practices, which can create variability in access even as clinical guidelines increasingly endorse molecular testing.

In Europe, the Middle East & Africa region, heterogeneity is pronounced across regulatory frameworks, reimbursement environments, and healthcare infrastructure. Certain European markets are characterized by centralized evaluation systems and national testing recommendations that can accelerate standardized adoption, while other markets in the broader region require localized validation and tailored commercial approaches. Manufacturers seeking presence across these diverse jurisdictions must balance regulatory harmonization with flexible market entry strategies that reflect regional reimbursement and laboratory capacity.

The Asia-Pacific region demonstrates a blend of rapid technology uptake in urban centers alongside ongoing development of diagnostic infrastructure in emerging markets. Public health initiatives and growing oncology patient volumes are encouraging investment in molecular diagnostic capabilities, while regional manufacturing hubs are expanding to serve both local and export demand. Across all regions, differences in sample logistics, laboratory accreditation practices, and clinician familiarity with genomic reports inform go-to-market planning. Therefore, regional strategies should weigh clinical guidelines, reimbursement pathways, supply chain resilience, and potential partnerships with local diagnostic networks to optimize adoption and scale.

Strategic competitive insights revealing how platform integrators, reagent specialists, bioinformatics providers, and laboratory networks are shaping market positioning and alliance opportunities

Competitive positioning in colorectal cancer molecular diagnostics reflects a spectrum of organizational archetypes that include established platform manufacturers, reagent specialists, bioinformatics firms, reference laboratory networks, and nimble startups. Platform manufacturers are investing in integrated solutions that couple sequencers or PCR systems with validated consumables and interpretation software to reduce implementation friction for clinical laboratories. Reagent and kit providers emphasize analytical performance, supply reliability, and streamlined workflows, which are critical for laboratories seeking consistent daily throughput and regulatory compliance.

Bioinformatics and data analytics companies are becoming indispensable partners, offering cloud-enabled variant interpretation, automation of reporting, and clinical decision support that can differentiate product offerings. Reference laboratories and centralized testing networks continue to play a dual role as both customers and collaborators; they often provide clinical validation studies, drive adoption through clinician engagement, and serve as launch partners for new assays. Emerging startups frequently focus on niche innovations-such as ultra-sensitive circulating tumor DNA assays or novel biomarker panels-that can be licensed or acquired by larger incumbents seeking to expand their portfolios.

Strategic alliances between technology vendors and clinical institutions are proving effective in bridging the gap between analytical performance and demonstrated clinical utility. These collaborations accelerate evidence generation, support payer discussions, and facilitate broader clinician acceptance. Overall, companies that align product development with scalable laboratory workflows, robust data interpretation, and clear clinical use cases will be best positioned to capture long-term value in a competitive environment.

Actionable strategic recommendations for product integration, supply chain resilience, evidence generation, and payer engagement to accelerate clinical adoption and commercial success

Industry leaders should prioritize integrated product offerings that marry analytical robustness with streamlined clinical workflows, ensuring that instruments, consumables, and software are validated as coherent solutions. Investing in turnkey assay packages that reduce laboratory setup complexity and provide clear interpretive guidance will lower adoption barriers for hospitals and diagnostic centers. Furthermore, companies should pursue clinical evidence generation that links assay results to actionable treatment decisions and demonstrable patient outcomes to strengthen reimbursement arguments and clinician trust.

Operationally, strengthening supply chain resilience is essential in an environment affected by tariff volatility and component shortages. This can be achieved through diversification of manufacturing locations, strategic inventory management, and long-term supplier agreements that include quality and delivery commitments. From a commercial standpoint, forming partnerships with reference laboratories and academic centers can accelerate validation and market entry while providing a channel for clinician education. Additionally, embedding advanced bioinformatics and decision-support tools into product offerings will enhance the clinical value proposition and enable scalable interpretation across diverse laboratory settings.

Finally, engaging proactively with regional regulatory bodies and payer stakeholders to align on evidence requirements and reimbursement pathways will reduce time-to-adoption. Manufacturers should build flexible commercialization playbooks that account for regional heterogeneity, including tailored pricing models, local validation packages, and collaborative post-market evidence collection. By executing these strategic imperatives, industry leaders can convert technological capability into sustained clinical and commercial impact.

Rigorous mixed-methods research approach combining expert interviews, systematic literature synthesis, and cross-validated quality checks to ensure clinical and commercial relevance

The research methodology underpinning this analysis combined qualitative expert engagement with systematic synthesis of public-domain scientific literature, regulatory documentation, and clinical guideline evolution. Primary inputs included structured interviews with key opinion leaders across clinical oncology, molecular pathology, bioinformatics, and laboratory operations to surface real-world adoption drivers, operational constraints, and unmet clinical needs. These expert perspectives were contextualized against peer-reviewed studies and regulatory notices to ensure alignment with current clinical practice and approval frameworks.

Secondary analysis involved a methodical review of technology performance characteristics, assay validation literature, and published clinical utility data to identify consistent trends and evidence gaps. Comparative evaluation of platform architectures, pre-analytical requirements for different sample types, and bioinformatics workflows informed assessments of integration complexity and laboratory suitability. Cross-validation of insights through multiple data sources and stakeholder voices was applied to reduce bias and enhance the robustness of conclusions.

Quality assurance measures included triangulation of primary and secondary findings, iterative review by subject-matter experts, and alignment checks against contemporary clinical guidelines and consensus statements. The research process prioritized transparency, reproducibility, and clinical relevance to produce actionable intelligence for business strategy and product development decisions in the colorectal cancer molecular diagnostics domain.

Synthesis of critical takeaways highlighting the intersection of technology maturation, evidence generation, supply chain resilience, and regional strategy that will dictate marketplace success

Colorectal cancer molecular diagnostics occupies a pivotal junction between advancing technological capability and the imperative to demonstrate clinical impact. Technologies such as next-generation sequencing and advanced PCR modalities offer complementary strengths that support a range of clinical applications from companion diagnostics to minimal residual disease monitoring. The maturation of bioinformatics and interpretation services has materially improved the clinical utility of molecular results, yet regional regulatory heterogeneity and payer variability continue to shape adoption trajectories.

Strategic responses to 2025 tariff changes and supply chain pressures underscore the need for operational agility, regional manufacturing considerations, and total-cost-of-ownership thinking. Companies that prioritize integrated solutions-bringing together reliable instruments, high-performing consumables, and validated interpretation software-will reduce implementation friction for laboratories and clinicians. Collaborative evidence generation with academic centers and reference laboratories will accelerate real-world validation and strengthen reimbursement discussions.

In closing, the path to broader clinical adoption lies in aligning technological innovation with demonstrable patient benefit, resilient supply chains, and pragmatic commercialization strategies that respect regional diversity. Stakeholders that successfully bridge these dimensions will be best positioned to influence care pathways and to realize long-term clinical and commercial value in colorectal cancer molecular diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Molecular Diagnostics Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Digital PCR
    • 8.4.2. Quantitative PCR

9. Colorectal Cancer Molecular Diagnostics Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. PCR Systems
    • 9.1.2. Sequencers
  • 9.2. Kits Reagents
  • 9.3. Software Services
    • 9.3.1. Bioinformatics Services
    • 9.3.2. Data Analysis Software

10. Colorectal Cancer Molecular Diagnostics Market, by Application

  • 10.1. Companion Diagnostics
  • 10.2. Predictive Testing
  • 10.3. Prognostic Testing
  • 10.4. Residual Disease Monitoring

11. Colorectal Cancer Molecular Diagnostics Market, by Biomarker

  • 11.1. BRAF
  • 11.2. KRAS
  • 11.3. Microsatellite Instability
  • 11.4. NRAS

12. Colorectal Cancer Molecular Diagnostics Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Serum
  • 12.2. Stool
  • 12.3. Tissue

13. Colorectal Cancer Molecular Diagnostics Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals Clinics
  • 13.4. Reference Laboratories

14. Colorectal Cancer Molecular Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Colorectal Cancer Molecular Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Colorectal Cancer Molecular Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Colorectal Cancer Molecular Diagnostics Market

18. China Colorectal Cancer Molecular Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies, Inc.
  • 19.6. Bio-Rad Laboratories, Inc.
  • 19.7. Exact Sciences Corporation
  • 19.8. F. Hoffmann-La Roche Ltd
  • 19.9. Guardant Health, Inc.
  • 19.10. Hologic, Inc.
  • 19.11. Illumina, Inc.
  • 19.12. Myriad Genetics, Inc.
  • 19.13. Qiagen N.V.
  • 19.14. Sysmex Corporation
  • 19.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 233. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 269. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO COLORECTAL